The Drug Discovery and Molecular Pharmacology (DMP) Study Section reviews cancer-related applications focused on the discovery, design, identification, isolation, development and/or synthesis of new molecular agents that are potentially useful in cancer therapy of solid tumors and leukemias. Agents may combat cancer by slowing cancer cell growth, hastening cancer cell death, sensitizing cancer cells to other therapies, inhibiting metastasis or angiogenesis, or ameliorating side effects. Agents may also contribute to the solubility or encapsulation of known cancer chemotherapies, or may improve the specificity of delivery of known chemotherapies to cancer cells. Studies designed to determine the efficacy of new drug combinations, or predict drug sensitivities, are also reviewed by DMP.
The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Novel drug discovery: identification of agents that target cancer cell processes; modulate cell signaling, hormone signaling or cell cycle; affect DNA damage, repair and/or replication; alter transcription factors and gene expression; affect differentiation, apoptosis, autophagy; diminish cancer cell metabolism; disrupt microtubule structure; determination of mechanism of action of novel agents that leads to translation of these agents in the clinic and validation of target
- New drug development and production: identification, synthesis and isolation of novel drugs and modification of existing compounds for evaluation in in vitro and/or in vivo tumor model systems
- Innovative technology development: advancement and application of new technologies for the drug discovery process, including microarray analysis, proteomics, genomics, and bioinformatics; development and application of new technologies for drug delivery
- Assay development: development of high throughput in vitro screens and cell-based assays for cancer therapeutics
- New molecular agents may include: synthetic small molecules; natural products; peptides or synthetic analogues; nucleic acids or synthetic analogues; antibodies or fragments; polymers, micelles or nanoparticles for solubility or encapsulation; viruses or bacteria, usually for delivery of active agents
Shared Interests and Overlaps
There are shared interests with Mechanisms of Cancer Therapeutics-1 (MCT1) and Mechanisms of Cancer Therapeutics-2 (MCT2) . Applications focused on determination of anti-cancer mechanisms or target identification may be assigned to MCT1 or MCT2. Applications intending to identify or synthesize new molecular entities may be assigned to DMP.
There are shared interests with Developmental Therapeutics (DT) . Applications to DT are focused on development of novel therapeutic strategies that have significant potential for early clinical translation. Applications intending to identify or synthesize new molecular entities may be assigned to DMP.
There are shared interests with Synthetic and Biological Chemistry A (SBCA) and Synthetic and Biological Chemistry B (SBCB) . Applications focused on new synthetic methods or targets, or structural analysis of biological macromolecules and their interactions with ligands or other macromolecules, may be assigned to SBCA or SBCB. Applications intending to examine the biological effects of new molecular agents in cells or animals may be assigned to DMP.
There are shared interests with Gene and Drug Delivery Systems (GDD) . Applications to GDD may be focused on any health issue or disease; DMP applications involving gene or drug delivery will be limited to anti-cancer therapies. DMP applications involving gene delivery will usually include a strategy involving a new molecular agent in addition to the delivered gene.
There are shared interests with the High-Throughput Screening Special Emphasis Panel ZRG1 BST-F (55) . Applications that focus on cancer immunomodulators or novel HTS assays for targets that have applicability to health issues or diseases other than cancer may be assigned to ZRG1 BST-F (55). Applications that focus on development of high throughput in vitro screens and cell-based assays for cancer therapeutics may be assigned to DMP.